ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2055

RBT-9 Antiviral Activity Against BK Virus

Session Information

Category: Transplantation

  • 1901 Transplantation: Basic

Authors

  • Ruiz, Stacey, Renibus Therapeutics, Inc., Southlake, Texas, United States
  • James, Scott, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Hartline, Caroll, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Singh, Bhupinder, University of California Irvine, Irvine, California, United States
Background

BK virus, a member of the polyomavirus family, is a significant risk factor for nephropathy and subsequent allograft loss in patients undergoing kidney transplantation. There are currently no approved treatments for BK virus-induced nephropathy. RBT-9, a novel formulation of stannous protoporphyrin (SnPP), exhibits broad antiviral activity against enveloped and nonenveloped viruses in vitro. It is also known to be protective against acute kidney injury (AKI) in animals when given prior to insult. Given the dual antiviral and kidney protective effects of RBT-9, the effect of RBT-9 against BK viral infection was investigated in vitro, as standard in vivo models that mimic BK virus complications are not currently available.

Methods

Two conditions were investigated: 1) standard qPCR-based antiviral assay – treatment with RBT-9 at the time of infection and 2) viral neutralization – pre-incubation of RBT-9 with BK virus for 1 hour prior to infection. RBT-9 was tested at concentrations up to 100 µM. Human foreskin fibroblast (HFF) cells were used as the host cell. Viral activity was assessed by real time qPCR and cellular viability was determined by CellTiter-Glo.

Results

RBT-9 exhibited moderate antiviral activity against BK virus under both treatment conditions. The 50% effective concentration (EC50) averaged 5.5 µM in 2 independently run standard qPCR assays and 5.4 µM in the neutralization assay. The EC50 of RBT-9 in these assays is 11 times lower than the highest dose of RBT-9 tested in Phase 1 studies and considered to be well tolerated. The 50% cytotoxic concentration (CC50) in the in vitro studies averaged 89.2 µM, indicating RBT-9 did not adversely affect host cell viability at concentrations 16.5 times higher than its effective concentration.

Conclusion

Given the antiviral activity of RBT-9 against BK virus in vitro and the safety profile of RBT-9 in Phase 1 human studies, a clinical study assessing the efficacy of RBT-9 is warranted in patients who are at risk of developing BK virus-induced nephropathy.

Funding

  • Other NIH Support –